Novel therapies including synthetically engineered multivalent bispecific antibodies (BsAbs) have been developed and are clinically approved to treat various cancers such as acute lymphoblastic leukemia [282] and small cell lung cancer [283], but currently no BsAbs have been approved and only limited to treat IgA-related disorders [284,285]. Here, CD79A is linked to cancer.